Idenix Pharmaceuticals LLC(NASDAQ : IDIX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.60%||163.54||0.7%||$1305.95m|
|LLY||Eli Lilly & Co.||-1.93%||323.65||1.1%||$1056.02m|
|BMY||Bristol-Myers Squibb Co.||-0.82%||71.12||1.0%||$763.08m|
|MRK||Merck & Co., Inc.||-0.52%||86.19||0.7%||$687.90m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-4.41%||200.16||8.2%||$210.64m|
|GBT||Global Blood Therapeutics, Inc.||0.04%||68.10||5.4%||$190.73m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.21%||151.22||0.0%||$178.64m|
|IDXX||IDEXX Laboratories, Inc.||-1.81%||325.80||3.9%||$175.84m|
|HZNP||Horizon Therapeutics Plc||-1.28%||61.89||5.4%||$160.55m|
|NVO||Novo Nordisk A/S||-0.74%||99.65||0.1%||$140.44m|
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).